190 related articles for article (PubMed ID: 20662098)
1. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.
Wang L; Liu JQ; Talebian F; El-Omrani HY; Khattabi M; Yu L; Bai XF
Eur J Immunol; 2010 Sep; 40(9):2569-79. PubMed ID: 20662098
[TBL] [Abstract][Full Text] [Related]
2. IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.
Wang LX; Talebian F; Liu JQ; Khattabi M; Yu L; Bai XF
Scand J Immunol; 2012 Mar; 75(3):273-81. PubMed ID: 22050574
[TBL] [Abstract][Full Text] [Related]
3. Effect of CD200 and CD200R1 expression within tissue grafts on increased graft survival in allogeneic recipients.
Yu K; Chen Z; Gorczynski R
Immunol Lett; 2013 Jan; 149(1-2):1-8. PubMed ID: 23178470
[TBL] [Abstract][Full Text] [Related]
4. Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.
Erin N; Podnos A; Tanriover G; Duymuş Ö; Cote E; Khatri I; Gorczynski RM
Oncogene; 2015 Jul; 34(29):3860-70. PubMed ID: 25263452
[TBL] [Abstract][Full Text] [Related]
5. The role of CD200-CD200R in tumor immune evasion.
Liao KL; Bai XF; Friedman A
J Theor Biol; 2013 Jul; 328():65-76. PubMed ID: 23541619
[TBL] [Abstract][Full Text] [Related]
6. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.
Bai XF; Liu J; Li O; Zheng P; Liu Y
J Clin Invest; 2003 May; 111(10):1487-96. PubMed ID: 12750398
[TBL] [Abstract][Full Text] [Related]
7. Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.
Liu JQ; Joshi PS; Wang C; El-Omrani HY; Xiao Y; Liu X; Hagan JP; Liu CG; Wu LC; Bai XF
J Immunol; 2010 May; 184(10):5435-43. PubMed ID: 20404277
[TBL] [Abstract][Full Text] [Related]
8. Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions.
Talebian F; Liu JQ; Liu Z; Khattabi M; He Y; Ganju R; Bai XF
PLoS One; 2012; 7(2):e31442. PubMed ID: 22319630
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
10. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
12. A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.
Liu JQ; Talebian F; Wu L; Liu Z; Li MS; Wu L; Zhu J; Markowitz J; Carson WE; Basu S; Bai XF
J Immunol; 2016 Aug; 197(4):1489-97. PubMed ID: 27385779
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.
Tahara H; Fujio K; Araki Y; Setoguchi K; Misaki Y; Kitamura T; Yamamoto K
J Immunol; 2003 Aug; 171(4):2154-60. PubMed ID: 12902522
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.
Vandermeulen G; Uyttenhove C; De Plaen E; Van den Eynde BJ; Préat V
Bioelectrochemistry; 2014 Dec; 100():112-8. PubMed ID: 24342164
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model.
Zhang X; Mei W; Zhang L; Yu H; Zhao X; Fan X; Qian G; Ge S
Oncol Rep; 2009 Nov; 22(5):1213-20. PubMed ID: 19787242
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.
Takayama T; Tahara H; Thomson AW
Transplantation; 2001 May; 71(9):1334-40. PubMed ID: 11397973
[TBL] [Abstract][Full Text] [Related]
18. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
Carayanniotis G; Halloran PF
Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
[TBL] [Abstract][Full Text] [Related]
19. The p815 mastocytoma tumor model.
Gajewski TF; Markiewicz MA; Uyttenhove C
Curr Protoc Immunol; 2001 May; Chapter 20():Unit 20.4. PubMed ID: 18432777
[TBL] [Abstract][Full Text] [Related]
20. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
